Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer.